Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOU064 Phase 2 study in chronic spontaneous urticaria
jRCT2080224713Phase 2Completed
- Start
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of remibrutinib in chronic idiopathic urticaria (CIU) (4 arms). Primary endpoint: Change from baseline in UAS7 at Week 4. Started Jun 2019; status: completed.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2080224713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224713.